Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
argenx signs billion-dollar deal with Janssen

Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody cusatuzumab. Unde…


UCB psoriasis drug approved for use in mothers

The UCB core drug CIMZIA® has just been approved by European Medicines Agency (EMA) for use in pregnant and breastfeeding mothers. The company has…


argenx launches Phase II study for cutaneous T-cell lymphoma therapy

argenx starts a new phase II clinical trial with ARGX-110, a SIMPLE antibody targeting CD70. ARGX-110 will be evaluated as a monotherapy for relap…

POPULAR TAGS

argenx launches Phase II study of ARGX-113 for the treatment of myasthenia gravis

Written by LVS on in the category news with the tags , , .


Llama antibody engineer argenx today announced the initiation of a Phase II proof-of-concept study of ARGX-113 in patients with myasthenia gravis (MG).

"MG is a rare and debilitating muscle disease with limited effective and sustainable treatments. ARGX-113 has the potential to eliminate patient symptoms while minimizing common side effects seen with current treatments by reducing the pathogenic IgG levels," commented Nicolas Leupin, CMO. "The initiation of this Phase II study is an important milestone in understanding how ARGX-113 can be effective in a wide range of IgG-mediated autoimmune diseases including additional orphan indications, and larger indications like multiple sclerosis and lupus. We expect to start a Phase II trial in a second orphan IgG driven indication, immune thrombocytopenia (ITP), by the end of the first quarter of 2017."

Read more about argenx.

The double-blind, placebo controlled Phase II study will enrol up to 24 MG patients with confirmed generalized muscle weakness. ARGX-113 will be dosed on top of current standard of care, corticosteroids and/or immunomodulatory agents. The primary endpoints of the trial are safety and tolerability and secondary endpoints include efficacy, impact on quality of life and an assessment of pharmacokinetics (PK) and pharmacodynamic (PD) markers.

In Phase I clinical trials, ARGX-113 demonstrated favorable safety and tolerability across multiple doses and dosing regimens with promising pharmacodynamics effects relating to speed, depth and duration of IgG reduction.

ARGX-113 is a potential breakthrough therapy for treatment of IgG-mediated autoimmune diseases. ARGX-113 is the Fc-portion of an antibody that has been modified by the argenx proprietary ABDEG™ technology to increase its affinity for FcRn beyond that of normal IgG antibodies. As a result, ARGX-113 blocks antibody recycling and leads to fast depletion of the autoimmune disease-causing IgG autoantibodies.

Read more about: , , .

RELATED ARTICLES
argenx signs billion-dollar deal with Janssen

Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody cusatuzumab. Unde…


UCB psoriasis drug approved for use in mothers

The UCB core drug CIMZIA® has just been approved by European Medicines Agency (EMA) for use in pregnant and breastfeeding mothers. The company has…


argenx launches Phase II study for cutaneous T-cell lymphoma therapy

argenx starts a new phase II clinical trial with ARGX-110, a SIMPLE antibody targeting CD70. ARGX-110 will be evaluated as a monotherapy for relap…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

KU Leuven UGent Biowin Itera Life Science Turnstone Janssen GSK XpandInnovation V-Bio Ventures Flanders.bio

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.